Core Viewpoint - The company has approved the initial list of incentive recipients for the 2025 restricted stock incentive plan, confirming compliance with relevant regulations and internal guidelines [1][2][3] Summary by Sections Public Announcement - The company held meetings on July 29, 2025, to review and approve the 2025 restricted stock incentive plan and its summary [1] - The public announcement of the initial list of incentive recipients was made from July 30 to August 8, 2025, through the internal OA system [2] - Employees were allowed to provide feedback via phone, email, written communication, or in person during the public announcement period [2] - No objections were received regarding the proposed initial list of incentive recipients by the end of the public announcement period [2] Verification Process - The company's remuneration and assessment committee verified the initial list of incentive recipients, including their identification documents and employment contracts with the company and its subsidiaries [2] - The verification confirmed that the information regarding the initial incentive recipients is accurate and does not contain any falsehoods or significant misunderstandings [3] Verification Opinions - The remuneration and assessment committee stated that the initial incentive recipients meet the qualifications set forth in the Company Law, Securities Law, and the company's articles of association [3] - The initial incentive recipients do not fall under any disqualifying conditions as outlined in the management regulations [3] - The recipients include directors, senior management, middle management, and other core personnel who have employment relationships with the company and its subsidiaries, excluding independent directors and major shareholders [3]

Summary of Key Points Core Viewpoint - The Supervisory Board of Yunnan Shennong Agricultural Industry Group Co., Ltd. has verified and publicly announced the list of incentive objects for the 2025 Restricted Stock Incentive Plan, confirming compliance with relevant regulations and the company's articles of association [1][2][3]. Group 1: Public Disclosure and Verification Process - The company held meetings on July 28, 2025, to approve the draft of the 2025 Restricted Stock Incentive Plan and publicly disclosed the list of incentive objects on the Shanghai Stock Exchange website on July 29, 2025 [1]. - The public announcement period lasted from July 29, 2025, to August 7, 2025, allowing employees to raise any objections to the proposed incentive objects [1][2]. - No objections were received from employees during the public announcement period [2]. Group 2: Supervisory Board's Verification Opinion - The Supervisory Board confirmed that all proposed incentive objects are current employees of the company and meet the qualifications stipulated by relevant laws and the company's articles of association [2]. - The basic information of the proposed incentive objects was verified as accurate, with no instances of falsehood or significant misrepresentation [2]. - The proposed incentive objects do not fall under any disqualifying conditions as outlined in the management regulations, such as being subject to market entry bans [2]. - The list of proposed incentive objects excludes independent directors, supervisors, foreign employees, and shareholders or actual controllers holding more than 5% of the company's shares [2][3].

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-041 江西三鑫医疗科技股份有限公司 第五届董事会第二十一次会议决议公告 本次会议审议通过以下议案： （一）审议通过《关于<2025 年半年度报告全文>及其摘要的议案》 经审议，董事会认为：公司《2025 年半年度报告全文》及《2025 年半年度 报告摘要》的内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假 记载、误导性陈述或者重大遗漏；报告的编制和审核程序符合法律、行政法规的 要求，符合中国证监会和深交所的相关规定。 具体内容详见公司于同日在中国证监会指定的创业板信息披露网站刊登的 《2025 年半年度报告全文》（公告编号：2025-039）、《2025 年半年度报告摘 要》（公告编号：2025-040），敬请广大投资者查阅。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 江西三鑫医疗科技股份有限公司（以下简称"公司"）第五届董事会第二十 一次会议已于 2025 年 7 月 26 日以书面方式通知全体董事，并于 2025 年 8 月 7 日以现场及远程方式在公司会议 ...

Meeting Overview - The 19th meeting of the 5th Supervisory Board of Jiangxi Sanxin Medical Technology Co., Ltd. was held on August 7, 2025, in compliance with relevant laws and regulations [1][2]. Financial Reporting - The Supervisory Board approved the company's 2025 semi-annual report, confirming that the report accurately reflects the company's actual situation without any false records or omissions [1][3]. Profit Distribution Plan - The company proposed a mid-term profit distribution plan, which includes a cash dividend of 1 yuan (including tax) for every 10 shares based on a total of 522,237,525 shares, after deducting 160,000 shares held in the repurchase account [2][3]. Stock Incentive Plan - The Supervisory Board approved the achievement of conditions for the first unlock period of the 2024 restricted stock incentive plan, allowing 112 eligible participants to unlock a total of 3,849,575 shares [3][4]. Convertible Bond Issuance - The company confirmed its eligibility to issue convertible bonds to unspecified investors, with a total fundraising target of up to 530 million yuan [5][6]. - The convertible bonds will be issued at face value, with a term of six years and an annual interest payment structure [6][7]. Fund Utilization - The proceeds from the bond issuance will be allocated to projects including the expansion of blood dialysis membrane production and the construction of high-performance blood purification equipment production lines, totaling 530 million yuan [17][18]. Governance and Compliance - The company established rules for the bondholders' meeting and outlined measures to mitigate the dilution of immediate returns for existing shareholders due to the bond issuance [21][22].

Core Points - The company has approved the first unlock period of the 2024 restricted stock incentive plan, confirming that the conditions for unlocking have been met [2][4] - A total of 112 individuals are eligible for the unlock, having satisfied the necessary conditions outlined in the incentive plan [3][4] - The company will adjust the repurchase price and cancel 313,250 shares of restricted stock that do not meet the unlock conditions [5] Summary by Sections Unlock Conditions - The company has verified that it meets the qualifications to implement the stock incentive plan and has not encountered any disqualifying events [2] - Specific disqualifying events include negative audit opinions, improper profit distribution, and other regulatory restrictions [2][3] Eligible Participants - The monitoring committee has confirmed that all 112 individuals on the unlock list meet the criteria set forth in the incentive plan [3][4] - The criteria include not being deemed inappropriate by regulatory bodies within the last 12 months and not having any major legal violations [3] Repurchase and Cancellation - The monitoring committee has approved the adjustment of the repurchase price for the restricted stock and the cancellation of shares that do not meet the unlock conditions [4][5] - The repurchase and cancellation process is deemed compliant with relevant regulations and will not adversely affect the company's financial status [4]

Core Viewpoint - The legal opinion letter from Jiangxi Huabang Law Firm confirms that Jiangxi Sanxin Medical Technology Co., Ltd. has fulfilled the necessary conditions for the first unlock period of its 2024 restricted stock incentive plan, including adjustments to the repurchase price and the repurchase and cancellation of certain restricted stocks [1][7][21] Group 1: Approval and Authorization - The company has obtained necessary approvals and authorizations for the first unlock period of the incentive plan, including the verification of the list of incentive recipients by the supervisory board [6][14] - The first unlock period for the restricted stocks begins 12 months after the completion of the stock grant registration [8][14] Group 2: Conditions for Unlocking - The conditions for unlocking the restricted stocks have been met, as the company did not receive any negative audit opinions or fail to distribute profits according to regulations [8][9][14] - The company achieved a revenue growth rate of at least 15% and a net profit growth rate of at least 10% compared to the previous year, fulfilling the performance targets set in the incentive plan [10][12][14] Group 3: Repurchase and Cancellation of Stocks - A total of 31.325 million shares of restricted stocks will be repurchased and canceled due to two incentive recipients leaving the company and 29 recipients not meeting the personal performance criteria [17][20] - The repurchase price for the restricted stocks is subject to adjustment based on the company's profit distribution plans, with the current price set at 3.5 yuan per share [19][20]

Core Viewpoint - The company has announced adjustments to the repurchase price of the 2024 restricted stock incentive plan and the repurchase and cancellation of certain restricted stocks due to changes in the eligibility of some incentive targets [1][10][11]. Summary by Sections Approval Procedures - The company has completed the necessary approval procedures for the 2024 restricted stock incentive plan, including discussions and approvals from the board and supervisory committee [1][3][10]. Repurchase and Cancellation Details - The repurchase involves 31.3250 million shares of restricted stock, with 19,000 shares being repurchased due to two individuals leaving the company and 12.325 million shares due to 29 individuals not meeting the release conditions [5][10][11]. Repurchase Price and Basis - The repurchase price is set at the grant price, which is 3.5 yuan per share. Adjustments to this price may occur based on the company's capital actions, such as dividends or stock splits [6][9][10]. Financial Impact - The repurchase and cancellation of restricted stocks are not expected to have a significant impact on the company's financial status or operational results, and the incentive plan will continue to be implemented [10][11]. Opinions from Committees - Both the board's remuneration and assessment committee and the supervisory committee have reviewed and approved the repurchase and cancellation actions, confirming compliance with relevant regulations [10][11][12].

Group 1 - The company held its 31st meeting of the 5th Board of Directors on August 8, 2025, via telecommunication voting, with all 9 directors present [1] - The board approved the repurchase and cancellation of 60,000 restricted stocks from a departing employee at a price of 4.73 yuan per share, which will also include interest at the bank's term deposit rate [1][2] - The board agreed to change the registered capital and amend the Articles of Association due to the cancellation of the restricted stocks, which will be submitted for approval at the upcoming extraordinary shareholders' meeting [2][3] Group 2 - The board approved the initial grant of restricted stocks under the 2025 incentive plan, with a total of up to 7.95 million shares to be granted at a price of 5.60 yuan per share, effective from August 8, 2025 [3] - The company will hold its 4th extraordinary shareholders' meeting on August 26, 2025, combining on-site and online voting methods [3]

因此，我们同意本次拟解除限售的激励对象名单，并同意公司为符合解除限 售条件的 47 名激励对象办理首次授予部分第一类限制性股票第一个解除限售期 解除限售事宜。 特此公告。 广东银禧科技股份有限公司 监事会 广东银禧科技股份有限公司 监事会关于 2024 年限制性股票激励计划首次授予 第一类限制性股票第一期解除限售激励对象名单的核查意见 广东银禧科技股份有限公司（以下简称"银禧科技"或"公司"）于 2025 年 8 月 7 日召开第六届监事会第十七次会议，审议通过了《关于 2024 年限制性股 票激励计划首次授予第一类限制性股票第一个解除限售期解除限售条件成就的议 案》，根据《公司法》《证券法》、《上市公司股权激励管理办法》（以下简称 "《管理办法》"）、等有关法律、法规和规范性文件以及《公司章程》的规定， 对公司 2024 年限制性股票激励计划第一期解除限售激励对象名单进行审核，发表 核查意见如下： 经审核，监事会认为：公司本次拟解除限售第一类限制性股票的 47 名激励对 象具备《公司法》《管理办法》等法律、法规和规范性文件及《公司 2024 年限制 性股票激励计划》（以下简称"《激励计划》"或"本激励计划" ...

Core Viewpoint - The legal opinion letter from Grandall Law Firm (Shanghai) confirms that Shanxi Qianyuan Pharmaceutical Group Co., Ltd. has obtained necessary approvals for the repurchase and cancellation of part of its restricted stock under the 2024 incentive plan, which is in compliance with relevant laws and regulations [1][9]. Group 1: Approval and Authorization of Repurchase - On May 16, 2024, the company's board of directors approved the draft of the 2024 restricted stock incentive plan and related proposals [5]. - On June 3, 2024, the company held a temporary shareholders' meeting to approve the incentive plan and related proposals [6]. - The board and supervisory committee verified the list of recipients for the restricted stock grants and the repurchase of stocks on subsequent meetings [6][9]. Group 2: Details of the Repurchase - The repurchase is based on the provision that if an incentive recipient leaves the company, the unvested restricted stocks will be repurchased at the grant price of 4.73 yuan per share, plus interest [7]. - A total of 60,000 shares will be repurchased due to one recipient's departure [7]. - The funds for the repurchase will come from the company's own funds [9]. Group 3: Conclusion and Compliance - The legal opinion concludes that the repurchase of restricted stocks has met the necessary approvals and is compliant with the relevant regulations and the incentive plan [9]. - The company must still complete the cancellation registration and related procedures as per the Company Law and fulfill information disclosure obligations [9].